Literature DB >> 6265513

Catecholamine-induced desensitization in turkey erythrocytes: cAMP mediated impairment of high affinity agonist binding without alteration in receptor number.

J M Stadel, A De Lean, D Mullikin-Kilpatrick, D D Sawyer, R J Lefkowitz.   

Abstract

Desensitization of turkey erythrocyte adenylate cyclase by exposure of these cells to the beta-adrenergic agonist isoproterenol leads to a decrease in subsequent adenylate cyclase stimulation by isoproterenol, F-, or Gpp(NH)p without any apparent loss or down regulation of receptors (B.B. Hoffman et al. J. Cyclic Nucl. Res. 5: 363-366, 1979). We now report that the desensitization is associated with a functional "uncoupling" of the beta-adrenergic receptor. This is evidenced by an impaired ability of receptors to form a high affinity, guanine nucleotide sensitive complex with agonist as assessed by computer analysis of radioligand binding data. The changes in adenylate cyclase responsiveness as well as the alterations in receptor affinity for agonists are reproduced by incubation of turkey erythrocytes with the cAMP analog 8-Bromo-adenosine 3':5'- cyclic monophosphate. These findings suggest that one possible mechanism for the development of desensitization in adenylate cyclase systems may be a cAMP mediated alteration of a component(s) of the beta-adrenergic receptor-adenylate cyclase complex which results in impaired receptor-cyclase coupling.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265513

Source DB:  PubMed          Journal:  J Cyclic Nucleotide Res        ISSN: 0095-1544


  14 in total

1.  Activation of adenylate cyclase in human platelet membranes by guanosine 5'-[beta gamma-imido]triphosphate is inhibited by cyclic-AMP-dependent phosphorylation. Slow activation occurs in the absence of ATP.

Authors:  R W Farndale; S K Wong; B R Martin
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

2.  The Gordon Wilson lecture. Adrenergic receptors: regulation at the biochemical, physiological and clinical levels.

Authors:  R J Lefkowitz
Journal:  Trans Am Clin Climatol Assoc       Date:  1983

3.  Photoaffinity labeling of the beta-adrenergic receptor from cultured lymphoma cells with [125I]iodoazidobenzylpindolol: loss of the label with desensitization.

Authors:  A Rashidbaigi; A E Ruoho; D A Green; R B Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

Review 4.  Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation.

Authors:  D R Sibley; R J Lefkowitz
Journal:  Mol Neurobiol       Date:  1987 Spring-Summer       Impact factor: 5.590

Review 5.  Reconstitution of the beta-adrenergic receptor.

Authors:  R J Lefkowitz; R A Cerione; J Codina; L Birnbaumer; M G Caron
Journal:  J Membr Biol       Date:  1985       Impact factor: 1.843

6.  Differential regulation of right and left ventricular beta-adrenergic receptors in newborn lambs with experimental cyanotic heart disease.

Authors:  D Bernstein; E Voss; S Huang; R Doshi; C Crane
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism.

Authors:  J A Heinsimer; A O Davies; R W Downs; M A Levine; A M Spiegel; M K Drezner; A De Lean; K A Wreggett; M G Caron; R J Lefkowitz
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

8.  Vasoactive-intestinal-polypeptide-stimulated adenosine 3',5'-cyclic monophosphate accumulation in GH3 pituitary tumour cells. Reversal of desensitization by forskolin.

Authors:  S Guild; A H Drummond
Journal:  Biochem J       Date:  1984-08-01       Impact factor: 3.857

9.  Functional alteration of the beta-adrenergic receptor during desensitization of mammalian adenylate cyclase by beta-agonists.

Authors:  S Kassis; P H Fishman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Acute reduction in human platelet alpha 2-adrenoreceptor affinity for agonist by endogenous and exogenous catecholamines.

Authors:  A S Hollister; G A FitzGerald; J H Nadeau; D Robertson
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.